briakinumab

Home
Ligands
briakinumab

GtoPdb Ligand ID: 9213

Synonyms: ABT-874 | J-695 | J695 | Ozespa

Comment: Briakinumab is a recombinant, fully human, IgG1 investigational monoclonal antibody targeting the shared p40 subunit of IL-12 and IL-23. Peptide sequences matching those of briakinumab are claimed in patent US6914128 'Human antibodies that bind human IL-12 and methods for producing' [2].

View more information in the IUPHAR Pharmacology Education Project: pericyazine

No information available.

No information available.

Summary of Clinical Use
Results from a Phase 2 clinical trial (NCT00292396) evaluating briakinumab in patients with moderate to severe chronic plaque psoriasis are reported in [1]. Several Phase 3 trials comparing briakinumab against placebo, etanercept and methotrexate (two approved anti-psoriatic drugs) for moderate to severe chronic plaque psoriasis (link here to a list of these trials on ClinicalTrials.gov) have been completed. Clinical development of briakinumab for rheumatoid arthritis, Crohn's disease and multiple sclerosis has been terminated. As of May 2017, there are no active clinical trials evaluating this antibody.

Summary of Clinical Use

Results from a Phase 2 clinical trial (NCT00292396) evaluating briakinumab in patients with moderate to severe chronic plaque psoriasis are reported in [1]. Several Phase 3 trials comparing briakinumab against placebo, etanercept and methotrexate (two approved anti-psoriatic drugs) for moderate to severe chronic plaque psoriasis (link here to a list of these trials on ClinicalTrials.gov) have been completed. Clinical development of briakinumab for rheumatoid arthritis, Crohn's disease and multiple sclerosis has been terminated. As of May 2017, there are no active clinical trials evaluating this antibody.

Clinical Trials
Clinical Trial ID	Title	Type	Source	Comment	References
NCT00292396	Efficacy and Safety of ABT-874 in Subjects With Moderate to Severe Chronic Plaque Psoriasis	Phase 2 Interventional	AbbVie